Dynamic Contrast-enhanced Magnetic Resonance Imaging As a Predictor of Clinical Outcome in Canine Spontaneous Soft Tissue Sarcomas Treated with Thermoradiotherapy
Overview
Authors
Affiliations
Purpose: This study tests whether dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters obtained from canine patients with soft tissue sarcomas, treated with hyperthermia and radiotherapy, are predictive of therapeutic outcome.
Experimental Design: Thirty-seven dogs with soft tissue sarcomas had DCE-MRI done before and following the first hyperthermia. Signal enhancement for tumor and reference muscle were fitted empirically, yielding a washin/washout rate for the contrast agent and tumor area under the signal enhancement curve (AUC) calculated from 0 to 60 seconds, 90 seconds, and the time of maximal enhancement in the reference muscle. These parameters were then compared with local tumor control, metastasis-free survival, and overall survival.
Results: Pretherapy rate of contrast agent washout was positively predictive of improved overall and metastasis-free survival with hazard ratio of 0.67 (P = 0.015) and 0.68 (P = 0.012), respectively. After the first hyperthermia washin rate, AUC60, AUC90, and AUCt-max were predictive of improved overall and metastasis-free survival with hazard ratio ranging from 0.46 to 0.53 (P < 0.002) and 0.44 to 0.55 (P < 0.004), respectively. DCE-MRI parameters were compared with extracellular pH and (31)P MR spectroscopy results (previously published) in the same patients showing a correlation. This suggested that an increase in perfusion after therapy was effective in eliminating excess acid from the tumor.
Conclusions: This study shows that DCE-MRI has utility predicting overall and metastasis-free survival in canine patients with soft tissue sarcomas. To our knowledge, this is the first time that DCE-MRI parameters are predictive of clinical outcome for soft tissue sarcomas.
Current Challenges in Image-Guided Magnetic Hyperthermia Therapy for Liver Cancer.
Sharma A, Cressman E, Attaluri A, Kraitchman D, Ivkov R Nanomaterials (Basel). 2022; 12(16).
PMID: 36014633 PMC: 9414548. DOI: 10.3390/nano12162768.
Dewhirst M, Oleson J, Kirkpatrick J, Secomb T Cancers (Basel). 2022; 14(7).
PMID: 35406473 PMC: 8997141. DOI: 10.3390/cancers14071701.
Advanced Cancer Imaging Applied in the Comparative Setting.
Vail D, LeBlanc A, Jeraj R Front Oncol. 2020; 10:84.
PMID: 32117739 PMC: 7019008. DOI: 10.3389/fonc.2020.00084.
Nolan M, Kent M, Boss M Front Oncol. 2019; 9:1291.
PMID: 31824863 PMC: 6883487. DOI: 10.3389/fonc.2019.01291.
Nolan M, Gieger T, Karakashian A, Nikolova-Karakashian M, Posner L, Roback D Technol Cancer Res Treat. 2017; 16(3):357-365.
PMID: 28168937 PMC: 5616052. DOI: 10.1177/1533034617690980.